#126049
Re: Farmas USA
KPTI
Noticia de hace tres días, pero la recojo porque se nos pasó y es importante.
National Comprehensive Cancer Network has added three different Xpovio combination regimens, include Xpovio with bortezomib and dexamethasone and Xpovio with daratumumab and dexamethasone, to its Clinical Practice Guidelines in Oncology
De hoy, designación de nuevo VP, con sus correspondientes stock options
Noticia de hace tres días, pero la recojo porque se nos pasó y es importante.
National Comprehensive Cancer Network has added three different Xpovio combination regimens, include Xpovio with bortezomib and dexamethasone and Xpovio with daratumumab and dexamethasone, to its Clinical Practice Guidelines in Oncology
De hoy, designación de nuevo VP, con sus correspondientes stock options
- appointment of Michael Mano as Senior Vice President, General Counsel. Mr. Mano brings over 15 years of legal experience and previously served as Counsel, Business Development at Biogen Inc.
"Michael's depth of legal experience, particularly in the public life science sector supporting partnerships, intellectual property licensing, corporate governance, and financing efforts, will be value to katiopharm as we continue to grow our commercial business and work to expand the reach of XPOVIO and our other pipeline assets worldwide," said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm.
Prior to Biogen, Mr. Mano served as Senior Counsel at Proskauer Rose LLP. Mr. Mano holds a Bachelor's degree from Saint Michael's College and a Juris Doctorate from Washington University in St. Louis ScNon-RevoNKPTLive
